Onyx Pharmaceuticals has agreed to purchase private biotechnology company Proteolix for $276 million in cash.
Positive Phase II Data for Peregrine’s Lung Cancer Treatment
Peregrine Pharmaceuticals reported positive Phase II data in a clinical trial of bavituximab in patients with a deadly form of lung cancer.
BioSante (NASDAQ: BPAX): LibiGel Provides Big Upside Potential
On 9/22/09, BioSante and Cell Genesys (NASDAQ: CEGE) announced that they have determined the final exchange ratio will be 0.1828 in connection with the previously announced merger between the companies.
FDA Approves Centocor’s Psoriasis Treatment
After a long delay, Centocor Ortho Biotech’s psoriasis drug Stelara has been approved by the U.S. Food and Drug Administration.
Melanoma Drug Called a “Breakthrough” After Study
Scientists are calling Plexxikon’s experimental skin cancer drug a “breakthrough” after it successfully shrank tumors in clinical trial patients.
Nasdaq Buoyed by Biotech
The Nasdaq rose 5 points on Monday, due in part to recent happenings in the biopharmaceutical sector.
FDA Approves Vermillion’s Ovarian Cancer Test
The U.S. Food and Drug Administration has approved a blood test to detect ovarian cancer and help physicians decide what kind of surgery should be done and by whom.
Sen. Kennedy Death Puts Focus On Brain Cancer
Glioblastoma multiforme (GBM), the aggressive brain tumor that took Sen. Kennedy’s life, is one of the deadliest brain tumors that can occur in both adults and children.
